UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 21, 2020
AVALON GLOBOCARE CORP.
(Exact name of registrant as specified in
its charter)
|
Delaware
|
|
000-55709
|
|
47-1685128
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number)
|
4400 Route 9 South, Suite 3100, Freehold,
New Jersey 07728
(Address of principal executive offices)
(zip code)
646-762-4517
(Registrant's telephone number, including
area code)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☒ Emerging
growth company
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbols
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value per share
|
|
AVCO
|
|
The Nasdaq Capital Market
|
On October 20, 2020, Avalon GloboCare Corp.
(the “Company”) entered into a Distribution Agreement with Adial Pharmaceuticals, Inc. (“Adial”) (the “Adial
Agreement”). Pursuant to the Adial Agreement, the Company was appointed as a non-exclusive sub-distributor of Adial’s
SARS-CoV-2 antibody tests and antigen tests and other medical devices and equipment worldwide. In consideration for such appointment
as a distributor, the Company agreed to evenly split with Adial all net profits from any revenue received from the sale of the
Adial devices. Mr. Stilley, a director of the Company as well as a member of the Nominating and Corporate Governance Committee
and Audit Committee, is the Chief Executive Officer and a director of Adial.
The foregoing is a summary
of the Adial Agreement and does not purport to be complete. The foregoing summary is qualified in its entirety by reference to
the full text of the Adial Agreement a copy of which is filed herewith as Exhibit 99.1.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
AVALON GLOBOCARE CORP.
|
|
|
|
|
|
Dated: October 21, 2020
|
By:
|
/s/ Luisa Ingargiola
|
|
|
|
Name: Luisa Ingargiola
|
|
|
|
Title: Chief Financial Officer
|
2
Exhibit 99.1
DISTRIBUTION AGREEMENT
THIS DISTRIBUTION AGREEMENT (this
“Agreement”) is made as of October 20, 2020 (the “Effective Date”) by and between Avalon GloboCare
Corp. (“Avalon”), a Delaware corporation with an office address at 4400 Route 9 South, Suite 3100, Freehold,
New Jersey 07728, USA, and Adial Pharmaceuticals, Inc. (“Adial”), a Delaware corporation with an office address
at 1180 Seminole Trail, Ste 495, Charlottesville, VA 22901. Avalon and Adial are each referred to as a “Party”
and collectively “Parties” to this Agreement.
WHEREAS, Avalon has expertise in
the development of diagnostics and therapeutic systems;
WHEREAS, Adial has and may acquire
certain rights to distribute and resell SARS-CoV-2 antibody tests and antigen tests and other medical devices and equipment (“Devices”)
manufactured by one or more third parties (“Manufacturer”); and
WHEREAS, Avalon and Adial wish to
enter into a strategic collaboration that appoints Avalon as a non-exclusive sub-distributor to Adial and provides Avalon certain
rights to distribute Devices under distribution by Adial.
NOW, THEREFORE, in consideration
of the mutual covenants contained herein and other good and valuable consideration the receipt and sufficiency of which is hereby
acknowledged, the Parties hereto hereby agree as follows.
|
|
1.
|
Distributor Rights. Adial agrees to appoint Avalon as a non-exclusive sub-distributor of the Adial Devices in the Territory
(as hereinbelow defined) and Avalon agrees to evenly split with Adial all Net Profits from any revenue received from the sale of
the Adial Devices by Avalon or an Avalon Affiliate as defined below:
|
|
|
a.
|
Profit Sharing Calculation. All Net Profits (as defined below) shall be distributed equally 50% to Adial and 50% to
Avalon on a monthly basis based on revenue received from the sales of the Devices made by Avalon or an Adial-approved Avalon affiliate.
As used herein, the term “Net Profits” shall mean: (a) gross revenues from payment actually received by Avalon (or
Adial-approved Avalon affiliate) from sales of the Devices “Gross Revenue”), less the cost of acquiring the kits by
Adial and less the following expenses (“Expenses”), (i) any shipping, freight or insurance expenses paid by a Party
to transport the Devices to a purchaser, (ii) any sales, ad valorem or value-added taxes paid by a Party and not reimbursed to
a Party by a purchaser of Devices, (iii) any customs duties, excise taxes or import tariffs paid by a Party; (iv) interest expense,
escrow fees, letter of credit charges and bank charges incurred by a Party to finance or transact the particular related sale,
and (v) broker fees or sales fees to third parties paid by either Party. The Parties shall be responsible for their own collection
and remittance to the appropriate federal, state or local authorities any income, sales, use or other taxes, if any, imposed in
connection with the distribution and sale of the Devices under this Agreement. The Parties will report to each other on a monthly
basis the Gross Revenue generated and Expenses incurred for sales of the Devices by Avalon (or an Adial-approved Avalon Affiliate),
and will make such payments to each other within 30 days after the end of each month so as to effectuate the revenue-sharing contemplated
by this Section.
|
|
|
b.
|
Affiliate. As used herein “affiliate” means, with respect to a particular Party, a person, corporation,
partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this
definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under
the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct
or cause the direction of the management and policies of such entity, whether by the ownership of more than fifty percent (50%)
of the voting stock of such entity, or by contract or otherwise. Avalon shall not be permitted to assign its rights and obligations
under this Agreement to an affiliate without prior written approval by Adial. Avalon shall be permitted to appoint Tauzin Consulting
and World Connect as agent affiliates to assist in the sale of the Devices. No other agents or brokers may be appointed by Avalon
without prior written approval by Adial.
|
|
|
2.
|
Territory. For the purposes hereof, the “Territory” shall mean worldwide.
|
|
|
3.
|
Customer Service. Adial or its designated service provider or partner will provide purchasers of the Devices from Avalon
(or an Adial-approved Avalon Affiliate), but not their retail end users, with its service support and other support services in
connection with the sale of the Devices.
|
|
|
4.
|
Term. The term of this Agreement is three (3) years (“Term”) unless earlier terminated by either Party upon
no less than one hundred and eighty (180) days written notice to the other Party.
|
|
|
5.
|
Warranties and Covenants. The Warranties and Covenants included within Exhibit 1 are included herein.
|
|
|
6.
|
Confidential Information.
|
|
|
a.
|
During the Term and for a period of three (3) years thereafter, each Party shall maintain the Confidential Information (as
hereinafter defined) of the other Party in confidence at all times, and shall not, directly or indirectly, whether in writing or
otherwise, communicate, publish, reveal, expose, divulge, or otherwise make available or permit the disclosure of the Confidential
Information, in whole or in part, to any person or entity, except as provided hereunder. The Parties shall not use the Confidential
Information, except for the express purposes permitted hereunder. In addition, each Party shall comply with all applicable health
care privacy rules and regulations and maintain the confidentiality of all health care and patient information and screening results.
|
|
|
b.
|
The term “Confidential Information” includes, but is not be limited to, all technical, business and other information
which one Party has disclosed or will disclose to the other Party, in written or other form, whether or not designated as “confidential”,
including all information and data pertaining to customer lists, supplier lists, technological, scientific or technical information,
inventions, know-how, trade secrets, designs, treatment protocols, clinical trials, patient data, materials used, sketches, components,
parts, hardware, software, research material, drawings, photographs, processes, specifications, operational data, models, prototypes,
contracts, costs, expenses, suppliers or transactions entered into, discussed or negotiated, business plans, budgets, forecasts,
feasibility studies, market plans, customers and other business, economic, financial or technological data, regardless of whether
such information, material or data or any part thereof is patentable or otherwise entitled to be registered in any official registry,
which is owned, developed or used by the disclosing Party and/or which is related to the disclosing Party, its business, services
or technology.
|
|
|
c.
|
Notwithstanding the foregoing, "Confidential Information" shall not include (i) information that, as of the time
of receipt, as evidenced by contemporaneous written documentation, is already known to, or in the possession of receiving Party
without restrictions imposed on its disclosure; and/or (ii) information that has been received by one Party without restrictions
on disclosure and in good faith from a third party who was lawfully in possession of the information and had the right to disclose
the same; and/or (iii) information that is independently developed by the receiving Party without use of or reference to the Confidential
Information of the disclosing Party, as evidenced by contemporaneous written documentation; and/or (iv) any information that has
entered public domain not as a result of the violations of the confidentiality undertaking by the receiving Party.
|
|
|
d.
|
In addition, the non-disclosure obligations pursuant to this Agreement shall not apply to Confidential Information that a receiving
Party is required to disclose pursuant to any judicial action, order of the court or other governmental agency; provided,
however, that the receiving Party shall make all reasonable efforts to notify the disclosing Party prior to the disclosure
of Confidential Information and allow the disclosing Party the opportunity to contest and avoid such disclosure, and further provided
that the receiving Party shall disclose only that portion of such Confidential Information that it is legally required to disclose
|
|
|
7.
|
Non-circumvention. Avalon agrees that Adial’s supplier and customer relationships related to the manufacture,
sale or distribution of Devices are critical assets of Adial. Adial agrees that the customer relationships of Avalon related to
the sale or distribution of Devices are critical assets of Avalon. Therefore and notwithstanding anything else herein for twelve
(12) months following termination of this Agreement: (i) Adial hereby agrees not to engage, either directly or indirectly (including,
without limitation, through any affiliate or an otherwise related party), in any discussions or negotiations, or to execute any
substantive agreement with a customer, or their affiliates, first contacted by Avalon (with documentation to support such identification
or contact) without the express prior written consent and approval of Avalon ; and (ii) Avalon agrees not to engage, either directly
or indirectly (including, without limitation, through any affiliate or an otherwise related party), in any discussions or negotiations,
or to execute any substantive agreement with a customer or supplier, or their affiliates, first contacted by Adial.
|
|
|
8.
|
Governing Law. Jurisdiction and Venue. This Agreement, and all matters arising directly or indirectly from this Agreement,
shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its conflict of laws
rules applicable to contracts to be performed entirely within the State of Delaware. The state or federal courts located in the
State of Delaware are the agreed-upon forum for the resolution of all disputes arising hereunder, and the Parties hereto, their
officers, and employees hereby consent to (i) the jurisdiction and venue of the aforesaid courts for the purpose of resolving all
such disputes and (ii) service of process by registered mail, return receipt requested, or any other manner consistent with federal
or Delaware law.
|
|
|
9.
|
No Agency. No agency, joint venture, partnership or employment shall be created by this Agreement, as the Parties are
independent contractors with respect to one another. Neither Party shall have authority to act as an agent of the other or to otherwise
bind the other to any agreement, commitment, obligation, contract, instrument, undertaking, arrangement, certificate or other matter.
|
|
|
10.
|
Miscellaneous. This Agreement shall not be modified or amended except in writing signed by the Parties. This Agreement
shall be binding upon and inure to the benefit of the Parties. This Agreement constitutes the entire agreement of the Parties with
respect to the subject matter hereof and supersedes any prior agreements. If any provision of this Agreement is determined to be
invalid or unenforceable in any respect, such determination will not affect such provision in any other respect, and the remainder
of the Agreement shall remain in full force and effect. In the interpretation of this Agreement, the ‘contra proferentem’
rule of construction will not apply (this Agreement being the product of negotiations between commercially sophisticated Parties)
and this Agreement will therefore not be construed in favor of or against any Party by reason of the extent to which any Party
or its professional advisors participated in the preparation and drafting hereof. This Agreement may be executed in counterparts
(including e-mail or facsimile counterparts), each of which shall be deemed an original but all of which together shall constitute
one and the same instrument.
|
IN WITNESS WHEREOF, the Parties have executed this Agreement
by their duly authorized officers as of the Effective Date
|
For Avalon GloboCare Corp.
|
|
For Adial Pharmaceuticals, Inc.:
|
|
|
|
|
|
|
|
By:
|
/s/ Luisa Ingargiola
|
|
By:
|
/s/ William Stilley
|
|
Print:
|
Luisa Ingargiola
|
|
Print:
|
William Stilley
|
|
Title:
|
CFO
|
|
Title:
|
CEO
|
Exhibit 1
Warranties and Covenants
Adial warrants and covenants that:
|
|
1.
|
Adial will pass on to Avalon, to the full extent provided by law, the Manufacturer’s standard limited warranty that the
Devices comply with all applicable laws and regulations in the U.S. and European Union, as the case may be;
|
|
|
2.
|
Adial will pass on to Avalon, to the full extent provided by law, the Manufacturer’s standard limited warranty that the
Devices conform to their published specifications and are free from defects in materials and workmanship, and any Devices determined
by the Parties to be defective shall be replaced by Adial with new Devices;
|
|
|
3.
|
to its knowledge, the Devices do not infringe any third-party rights and will not subject Avalon to liability for violation
of any laws, rules or regulations;
|
|
|
4.
|
Adial shall have good and marketable title to the Devices to be resold by it to Avalon; and
|
|
|
5.
|
Adial shall indemnify and hold harmless Avalon and its respective directors, officers, agents and employees from and against
any and all liabilities, claims, suits, losses, damages or causes of actions including costs, attorney fees and expenses that may
be suffered by any loss, damage, death or bodily injury (collectively the “Liability”) directly and proximately caused
by a breach of the representations or warranties contained herein, claims asserting that a Test infringes the intellectual property
of any other person or entity; or that use of the Devices resulted in bodily injury, including without limitation, personal injury
and death (unless any such Liability is caused by Avalon's gross negligence or willful misconduct), or the non-performance or improper
performance by Adial of any of its obligations arising out of or in connection with this Agreement; provided, however,
that in no event shall Adial be liable to Avalon or any other entity for any special, consequential, incidental, or indirect damages,
including lost profits, however caused, on any theory of liability; provided, further, that Adial shall not indemnify
Avalon for any loss and/or litigation expense that is connected in any way to an end-user operation of a test in which such end-user
does not operate a testing laboratory deemed eligible to perform moderate complexity tests and/or high complexity tests in accordance
with any and all applicable laws, statutes and/or regulations.
|
Avalon warrants and covenants that:
|
|
1.
|
it shall comply with any and all applicable statutes and regulations of any federal, state or other governmental entity or
agency connected in all respects with Avalon’s (a) use of the Devices and/or (b) sale of the Devices to any third-party purchasers;
|
|
|
2.
|
it shall at all times indemnify Adial against all Liability (as defined above) caused by any breach of any of the representations
or agreements made by Avalon under this Agreement or the non-performance or improper performance by Avalon of any of its obligations
arising out of or in connection with this Agreement; provided, however, that in no event shall Avalon be liable to
Adial or any other entity for any special, consequential, incidental, or indirect damages, including lost profits, however caused,
on any theory of liability; and
|
|
|
3.
|
any and all of the Devices sold by Adial to Avalon shall be utilized in accordance with all applicable Clinical Laboratory
Improvement Amendments (“CLIA”), and, when applicable, shall only be utilized by end-users operating laboratories deemed
eligible in accordance with any and all applicable laws, statutes and/or regulations. IT IS HEREBY UNDERSTOOD BY AVALON THAT ADIAL
SHALL NOT INDEMNIFY AVALON FOR ANY LOSS AND/OR LITIGATION EXPENSE THAT IS CONNECTED IN ANY WAY TO AN END-USER OPERATION OF A TEST
IN WHICH SUCH END-USER DOES NOT OPERATE A TESTING LABORATORY DEEMED ELIGIBLE TO PERFORM MODERATE COMPLEXITY TESTS AND/OR HIGH COMPLEXITY
TESTS IN ACCORDANCE WITH ANY AND ALL APPLICABLES LAWS, STATUTES AND/OR REGULATIONS. AVALON SHALL INDEMNIFY ADIAL FOR ANY LOSS AND/OR
LITIGATION EXPENSE INCURRED BY ADIAL IN CONNECTION WITH AVALON’S SALE OF A TEST TO A THIRD-PARTY PURCHASER AND/OR END-USER
OF A TEST THAT USES AND/OR OPERATES SAID TEST NOT IN COMPLIANCE WITH ANY AND ALL APPLICABLE LAWS, STATUTES AND/OR REGULATIONS.
|
-5-
Exhibit 99.2
Avalon GloboCare and Adial Pharmaceuticals
Announce Strategic Collaboration
for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices
Assure/Fastep® COVID-19 Point-of-Care
Antibody Test is the First Test Granted FDA Emergency
Use Authorization for Use with Fingerstick Blood Samples
FREEHOLD, NJ AND CHARLOTTESVILLE, VA, October
22, 2020 -- Avalon GloboCare Corp. (NASDAQ: AVCO) (“Avalon”), a clinical-stage, global developer of cell-based
technologies and therapeutics and Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage
biopharmaceutical company focused on the development of treatments for addiction, today announced formation of a strategic collaboration
for global distribution of the Assure/Fastep® COVID-19 IgG/IgM Rapid Test device and the Assure/EcoStep® COVID-19 IgG/IgM
Rapid Test device, point-of-care (POC) COVID-19 antibody tests. The FaStep COVID-19 IgG/IgM Rapid Test Device is the first serology
(antibody) POC test for COVID-19 using fingerstick blood samples approved by the U.S. Food and Drug Administration (FDA), which
has issued an emergency use authorization (EUA) for the FaStep COVID-19 IgG/IgM Rapid Test Device and the EcoStep COVID-19 IgG/IgM
Rapid Test Device. Under the agreement, Adial has granted Avalon non-exclusive, sub-distribution rights worldwide for the FaStep
COVID-19 IgG/IgM Rapid Test Device and the Assure/EcoStep COVID-19 IgG/IgM Rapid Test Device, POC COVID-19 antibody tests.
As a result of the FDA’s EUA, fingerstick
blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors’
offices, hospitals, urgent care centers, emergency rooms, or other locations where there is a licensed healthcare professional.
The FaStep COVID-19 IgG/IgM Rapid Test Devices are lateral flow assay, 10-minute, ‘instant,' POC test devices for the qualitative
detection of lgG and lgM antibodies specific to SARS-CoV-2 virus in fingerstick whole blood, venous whole blood, serum, and plasma.
During testing, the specimen reacts with antigen coated particles in the test cassette after droplets of blood from the subject
are placed on the cassette’s coated membrane.
“We believe there is significant market
potential for these differentiated test kits, as these tests are able to detect IgG antibodies at a 98.6% accuracy and IgM antibodies
at a 92.9% accuracy and provide results within 10-minutes,” said David Jin, M.D., Ph.D., President and Chief Executive Officer
of Avalon. “Our goal is to leverage our international distribution network and channel partners to bring the product to market
globally.”
William Stilley, Chief Executive Officer of
Adial, commented, “We are pleased to enter into this strategic collaboration with Avalon. Avalon has an established global
distribution network that we believe will facilitate further sales of these COVID-19 Rapid Test Devices worldwide. The rapid proliferation
of COVID-19 around the world has driven demand for SARS-CoV-2 detection, and a widespread need for rapid antibody testing. We look
forward to working with Avalon in order to help meet the global demand for rapid result COVID-19 serology testing.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a
clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative
immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides
strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness
in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative
R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of
cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information
about Avalon, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments, please
follow them on twitter using their Twitter Handle: @avalongc_avco
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL;
ADILW) is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s
lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for
the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal
Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified
using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of
AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance),
and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to
have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. www.adialpharma.com
Forward-Looking Statements
This communication contains certain "forward-looking
statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived
utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different from any future results, performance or achievements expressed
or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes,"
"expects," "anticipates," "intends," "projects," "estimates," "plans"
and similar expressions or future or conditional verbs such as "will," "should," "would," "may"
and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements
include the foregoing. The forward-looking statements include statements regarding leveraging Avalon’s international distribution
network and channel partners to rapidly and cost effectively bring the product to market globally, Adial working with Avalon in
order to help meet the global demand for rapid result COVID-19 serology testing and the potential of AD04 to treat other addictive
disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current
views, and they involve certain risks and uncertainties, including, among others, Avalon’s ability through its international
distribution network and channel partners to rapidly and cost effectively bring product to market globally, Adial’s and Avalon’s
respective ability to meet the global demand for rapid result COVID-19 serology testing, Adial’s ability to enroll patients
and complete clinical trials on time and achieve desired results and benefits, Adial’s ability to obtain regulatory approvals
for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating
to its ability to promote or commercialize its product candidates for specific indications, Adial’s [and Avalon’s]
respective ability to maintain its license agreements, continue maintenance and growth of its patent estate and to establish and
maintain collaborations, Adial’s and Avalon’s respective ability to obtain or maintain the capital or grants necessary
to fund its research and development activities, and Adial’s and Avalon’s respective ability to retain its key employees
or maintain their Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other
cautionary statement included in Adial’s Annual Report on Form 10-K for the year ended December 31, 2019, subsequent Quarterly
Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission and Avalon’s Annual
Report on Form 10-K for the year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q and current reports on Form
8-K filed with the Securities and Exchange Commission . Any forward-looking statement speaks only as of the date on which it was
initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new
information, future events, changed circumstances or otherwise, unless required by law.
Avalon Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Avalon Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
Adial Contact Information
Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com
